Ask AI
ProCE Banner Activity

Key Updates on PBC Management From ACG and AASLD 2025

Clinical Thought

The 2025 ACG and AASLD meetings presented encouraging data on therapies for primary biliary cholangitis (PBC) and its symptoms, offering real hope for patients who, until recently, had very limited treatment options. Here, I highlight the findings that may change both our clinical approach and our expectations for long-term outcomes in PBC.

Released: December 24, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc. and Ipsen Biopharmaceuticals, Inc.

Gilead Sciences, Inc.

Ipsen Biopharmaceuticals Inc

Target Audience

This activity is intended for physicians, including hepatologists and gastroenterologists; nurse practitioners; physician associates; nurses; and other healthcare professionals involved in the care of patients with PBC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply new advances in PBC to clinical practice

  • Formulate patient management strategies based on up-to-date understanding of new and emerging agents for PBC, including mechanisms of action, clinical data, safety, and place in therapy

Disclosure

Primary Author

Nancy Reau, MD: consultant/advisor/speaker: Gilead, GSK, Ipsen, Mallinckrodt, Salix, Vir; researcher: Bluejay, Salix, Vir.